And in the end, the love you take, is equal to the love… you make.
Copenhagen
Joined November 2010
- Tweets26.4K
- Following330
- Followers3.8K
- Likes37.9K
Pinned Tweet
$NWBO
The miracle of Braelyn
With help from Braelyns mother Amanda, we have made a presentation, that documents Braelyns incredible journey the last 3 years.
Please share.
There is a link to donation site, if you would care to help 🙏
nwbo-community.com/news/15c6…
$NWBO
If you have the means, please support with what you can, or reshare.
Glioblastoma patients have had almost no alternatives the last 30 years.
It’s time to end this cycle and create hope.
My "someone" is my daughter. She is the mother of 2 boys, 1 yr and 3yrs old. The logistics and finances it would take to get her to the UK are nearly insurmountable. Please. I don't want to lose my precious daughter when she should have access to DCVax through Right to Try right here in the US.
@POTUS
@RobertKennedyJr
$NWBO
🇩🇰 The Danish Dude 🇬🇱 retweeted
🚨🇺🇸 BRAELYN’S STORY JUST MADE FOX BUSINESS! 🇺🇸🚨
What an incredible moment for our family!
Today on Varney & Co., Stuart Varney brought up Steve Moore’s recent Rasmussen Reports article about Braelyn and the barriers seriously ill Americans face in accessing promising experimental treatments!
Steve shared Braelyn’s story and called out the FDA, saying it’s CRUEL to withhold promising investigational treatments from desperately ill patients.
Varney agreed, arguing that patients facing terminal illnesses should have the freedom to accept the risks of experimental treatments without liability concerns preventing companies from providing them.
Then Steve asked a powerful question:
“Whatever happened to my body, my choice?”
He also pointed out that President Trump supports Right to Try, yet significant barriers remain between patients and the treatments they desperately need.
THIS is the conversation we’ve been fighting to bring into the national spotlight!
Our 19-year-old daughter is attending college, and her latest MRI shows no evidence of cancer recurrence. Yet we still have to travel to ENGLAND for her ongoing DCVax-L treatments—developed right here in AMERICA!
We are so incredibly grateful to Steve Moore and Stuart Varney for bringing attention to Braelyn’s story and, more importantly, to the countless patients who deserve a fighting chance.
Patients facing life-threatening illnesses shouldn’t have to fight their own government for the opportunity to fight for their lives.
PLEASE WATCH AND SHARE! ❤️🙏
@realDonaldTrump @DrOzCMS @SecKennedy
#DCVaxForBraelyn #RightToTry #DCVax
#BraelynsFight
$NWBO
I’d actually pay to see him, if he just labeled it as a stand up comedy tour.
$NWBO
🙏🏻 if you can, please help
❤️ SUNDAY MORNING UPDATE — WE’RE GETTING SO CLOSE! ❤️
In just 12 days, Braelyn will receive her next DCVax-L treatment in London!
Since my last fundraising update, more generous people have stepped forward to help us continue her treatment. We are overwhelmed by your kindness and generosity!
I’ve carefully reconciled our treatment fund, GoFundMe, GiveSendGo, and private donations to share where we stand.
🎯 Estimated November 6 treatment cost: $30,844
❤️ TOTAL FUNDS ACCOUNTED FOR: $26,308.02
🎯 ESTIMATED AMOUNT STILL NEEDED: $4,535.98
That’s more than 85% of November’s treatment covered!
These figures include donations already deposited, contributions still processing through our fundraising platforms, and private gifts received but not yet deposited.
Because treatment is billed in British pounds, the final dollar amount may vary slightly depending on exchange rates and fees.
When I look at Braelyn today—cancer-free, attending college, and looking forward to her future—I am reminded why we continue fighting so hard for access to DCVax-L.
Thank you to everyone who has donated, shared her story, prayed for her, or encouraged our family. Your generosity has helped make this journey possible.
We’re getting so close to covering her November treatment!
If you’re able to help us close the remaining gap, we would be incredibly grateful. Every donation, regardless of size, and every share makes a difference.
Thank you for helping give Braelyn hope and a future. ❤️🙏
#DCVaxForBraelyn #DCVax #BrainCancer
$NWBO
"... while also gaining early insight into a series of significant MHRA announcements that will set out the Agency’s ambitions for world-leading regulatory science and innovation."
gov.uk/government/news/dia-a…
🤖 Made with AI
$NWBO
We have a newer FUD account at large today. Looks like Frosty should’ve stayed home today.
investorshub.advfn.com/board…
First, MHRA itself confirmed on July 20 that DCVax-L remained under initial regulatory review, had never been refused, withdrawn or appealed, and was progressing toward its first regulatory decision. That’s an official regulatory statement, not Linda Powers’ interpretation.
Second, a provisional CHM letter is legally distinct from rejection. Even if one exists, NWBO’s statement remains consistent with MHRA’s confirmation.
Third, the supposed MHRA leak to Feuerstein is pure conjecture. No source, document or evidence. The suggestion that STAT leaving his article online somehow proves inside knowledge is equally absurd.
Fourth, accusing Linda Powers of knowingly deceiving investors to facilitate share issuance is an extraordinarily serious allegation supported by precisely zero evidence of her alleged intentions.
And then there’s October 8.
NHS Blood and Transplant publicly confirmed its operational DCVax-L manufacturing collaboration in Leeds and Oxford, with further expansion under discussion.
We’ve also established that MHRA and NHSBT cooperate on medicines supply, while MHRA has formal mechanisms for sharing anticipated regulatory decision dates with designated NHS organisations.
This makes coordinated preparations for patient access entirely plausible, although DCVax-L-specific information sharing remains unconfirmed.
So we’re supposed to believe NWBO was secretly concealing an impending regulatory disaster while a major NHS institution publicly expanded its involvement in preparing DCVax-L production?
The bullshit these fudders tries to sell on a Sunday. Everyday is a Judas coin earning day.
The documented facts are MHRA’s confirmation of an ongoing initial review and NHSBT’s manufacturing involvement.
Keep calm and carry on. The fudders are working overtime.
Anyone who are still not convinced Russia is in charge of Trump ... please leave the room.
US foreign policy rests on ... no not politics, just simple self enrichement scheme. To line own, family and friends pockets, while selling out countries to the enemy and in the process, lying about it, lying about anything.
If this administration is not put on trial, when their autocratic reign hopefully one day ends, then "say goodbye to hollywood".
My God ... how can any american, any republican who have ever looked up to Reagan and his view on the old USSR, in any way, defend what is openly going on?
Ignorance. Plain ignorance, is the key. A dumbing down of a whole civilisation through social media, leading to cult like manners.
Jesus H.
thedailybeast.com/secret-rus…
US energy company execs have resigned in disgust as the Trump family is caught secretly expediting the funneling of $25 billion from a sanctioned Russian energy giant in exchange for allowing Russians to obtain a natural gas project in Alaska.
According to investigations by The New York Times and Financial Times, Russia's Novatek allegedly concealed its financial involvement in the American project through a UAE-linked intermediary.
Gentry Beach, a longtime Trump ally and close friend of Donald Trump Jr., signed an agreement with Novatek to pursue natural gas development in Alaska. Reuters documented the arrangement in February.
Meanwhile, Vladimir Putin discussed this cooperation on the Alaska energy project with Trump's representatives, Steve Witkoff and Jared Kushner, during negotiations involving Russia and Ukraine.
The controversy deepened when Polar Train LNG's CEO, Joel Riddle, raised concerns about concealed Russian financing and possible sanctions violations. He departed in September, followed by other senior executives.
The Financial Times also described discussions about a potential arrangement under which Novatek would provide technology for the Alaska project in exchange for sanctions relief benefiting its Arctic LNG 2 development in Siberia.
According to The New York Times, Riddle and two other departing executives warned the Trump administration about the Russian financing and urged officials to investigate.
The White House maintains that the project was mentioned only briefly and that no detailed discussions took place. There is no established evidence that Kushner or Witkoff knew about the allegedly concealed financing. Polar Train LNG denies wrongdoing.
The central question is how a sanctioned Russian energy company became involved in a major American energy venture while Putin was discussing potential economic cooperation with Trump's representatives and a longtime Trump family associate was pursuing a separate agreement with the same Russian company.
Selling Alaska to the Russians or selling Ukraine to the Russians - to the Trump family it's all the same.
ft.com/content/e9cfbfbb-e65a…
$NWBO
It's sunday and exwannabe - aka brazen22 - numere uno fudder of all time, is ofcourse active, trying to sow fear, uncertainty and doubt. He is running out of rational options, so he turns to rhetorical ones, making him sound wiser, than he is.
SO ...
The August CHM minutes confirm unresolved concerns. They say absolutely nothing about whether those concerns involve clinical data, manufacturing, potency or comparability.
The oral hearing is a genuine opportunity to resolve those questions before a final decision.
Meanwhile, NHSBT has publicly confirmed operational support for DCVax-L production in Leeds and Oxford, with further expansion under discussion. NWBO has consolidated Advent, advanced Flaskworks automation and continued preparing for commercialization.
The UK also has established mechanisms for coordinating regulatory timelines with NHS preparations.
A substantial body of positive, tangible developments.
The bullish case rests on documented progress, while the rejection narrative rests on assumptions about confidential CHM concerns that nobody outside the process has established.
The fudders are trying so hard to make you worried.
They want your shares SO badly and SO cheap.
exwannabe has been fighting 12 years for Judas coins, and it becomes increasingly more difficult for him, to have a valid legitimate critical perspective.
So ... let's try to sound smarter than we are.
That's the fud narrative of the week.
I say ... f*** him and the horse he rode in on. You can be sure the fud collective are going to be active today, preparing for next weeks oral diarrhea.
$NWBO
The idea that MHRA has effectively decided to reject DCVax-L simply doesn’t fit the evidence we actually have.
The August CHM minutes mention unresolved concerns about an unidentified glioblastoma treatment. They say absolutely nothing about external controls, propensity analysis or manufacturing. Claiming that CHM rejected NWBO’s July statistical findings is pure speculation.
Now consider what has actually happened.
Following the most likely September oral hearing window, NHS Blood and Transplant publicly confirmed its active involvement in DCVax-L production, initially in Leeds and Oxford, while discussing expansion to additional locations.
That’s a significant development. NHSBT is a major public healthcare institution committing real operational resources to supporting this treatment.
We’ve also established that MHRA and NHS organisations have formal arrangements for coordinating preparations ahead of regulatory decisions. That makes the timing particularly interesting, even though the precise information shared about DCVax-L remains unknown.
Meanwhile, NWBO has consolidated ownership of Advent, continues developing Flaskworks automation and has added capital-markets expertise potentially relevant to future exchange plans.
These are tangible preparations for commercialization.
Would a company expecting an imminent regulatory rejection continue publicly advancing an NHS-supported manufacturing network? It’s possible, but hardly the most compelling interpretation of these developments.
The oral-representation process also exists to give applicants an opportunity to resolve outstanding objections. Successful precedents demonstrate that serious regulatory questions can ultimately lead to approval.
The evidence supports a company actively preparing for commercial readiness while its regulatory review continues.
The CHM concerns deserve attention. But turning an unidentified objection into a supposed rejection of NWBO’s clinical evidence, while disregarding the company’s substantial operational progress, requires far more assumptions than the facts justify.
The bullish case is increasingly tangible.
In short … looking good 👍🏻
$NWBO
Did we just find the missing link on a RELATIONSHIP between NHSBT and MHRA?
If so, the news on NHSBT manufacturing support might have stemmed from the MHRA regulatory process.
Thanks to red_right_hand on Ihub for finding this.
gov.uk/government/publicatio…
There is a documented working relationship between NHSBT and MHRA.
In July 2026, they jointly announced a regulatory decision on plasma medicines, bringing together MHRA’s safety assessment and NHSBT’s plans to strengthen supplies. This demonstrates direct cooperation over getting treatments to patients.
MHRA also has a formal system for sharing estimated decision dates with NHS England and other named health organisations, with the applicant’s consent. The purpose is straightforward: help the NHS prepare services ahead of a decision so patients can access newly approved treatments sooner.
NHSBT’s government framework reinforces this approach, specifically identifying collaboration with partners to develop and expand NHS services as a strategic objective.
For NWBO, this makes NHSBT’s reported involvement in DCVax-L cell collection and processing at Leeds and Oxford, alongside discussions about expansion, particularly encouraging. These activities address practical requirements for delivering a personalised treatment to more patients.
The remaining gap is whether these connections were used to share information specifically about DCVax-L. NHSBT sits outside the information-sharing scheme’s named recipients, and onward disclosure is restricted. That requires separate evidence.
A bullish interpretation is that DCVax-L is gaining practical NHS support within a health system designed to coordinate preparation around regulatory decisions. That strengthens the commercial-readiness story and makes coordinated planning plausible.
Confirmation of a favourable CHM outcome remains the decisive missing piece.
Sources
1. MHRA and NHSBT joint announcement, July 2026 Demonstrates direct cooperation between MHRA and NHSBT concerning regulatory decisions and medicine supplies. GOV.UK - MHRA safety review gives UK plasma donations go-ahead
2. MHRA Operational Information Sharing Guidance, January 2026 Establishes how MHRA shares anticipated regulatory decision dates with NHS England and other designated health organisations to support preparations for patient access. GOV.UK - Operational Information Sharing Guidance
3. DHSC and NHSBT Framework Agreement, September 2025 Documents NHSBT’s formal relationship with the Department of Health and Social Care and its responsibilities for collaboration, service development and operational planning. GOV.UK - DHSC and NHSBT Framework Agreement
4. NHSBT Chief Executive’s Board Report, July 21, 2026 Documents cooperation between NHSBT, NHS England and DHSC concerning medicines supply and operational capacity. NHSBT - Chief Executive’s Public Board Report (PDF)
5. NHSBT announcement on DCVax-L, October 2026 Confirms NHSBT’s involvement in immune-cell collection and processing supporting DCVax-L production, initially involving Leeds and Oxford, with further expansion being explored. NHSBT - Specialist Therapeutic Apheresis and Cell Processing Support for DCVax-L
6. Northwest Biotherapeutics announcement, October 8, 2026 Provides NWBO’s account of the NHSBT collaboration and the preceding months of joint preparation. NWBO - Collaboration with NHS Blood and Transplant
Important distinction: These sources document institutional coordination and DCVax-L manufacturing preparations.
$NWBO
NYTimes has this article.
nytimes.com/2026/10/23/well/…
I wrote this comment, but somehow I feel quite sure it won't get approved.
Now it's your turn.
Use your voice and write a comment here:
nytimes.com/2026/10/23/well/…
$NWBO
Read about a couple of interesting "participators" in the August CHM, one with relations to earlier manufactoring of DCVax-L.
nwbo-community.com/posts/37d…
Very interesting.
Farzin as hired with Keyoumars Ashkan related to manufactoring of DCVax-L.
AND he not only shared employment at King's College with Ashkan, they actually co-authored a scientific paper:
Active dendritic cell immunotherapy for glioblastoma: Current status and challenges
Published in the British Journal of Neurosurgery, volume 29, pages 197-205 (2015).
tandfonline.com/doi/full/10.…
